The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...
Many patients with myeloma respond well to treatment, starting with strategically combined medications, followed by a stem cell transplant and, eventually, ongoing maintenance therapy to stave off ...